Acthrel for Cushing's Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Cushing's Disease+6 More
Acthrel - Drug
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether giving the hormone CRH before a PET scan can help make pituitary gland tumors more visible.

Eligible Conditions
  • Cushing's Disease
  • Pituitary Adenoma

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Baseline

Baseline
CRH-stimulated PET imaging demonstrates tumor in MRI-negative cases.
Elevation of SUV of 18F-FDG

Trial Safety

Trial Design

1 Treatment Group

1
1 of 1

Experimental Treatment

22 Total Participants · 1 Treatment Group

Primary Treatment: Acthrel · No Placebo Group · N/A

1
Drug
Experimental Group · 1 Intervention: Acthrel · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Corticorelin ovine triflutate
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline

Who is running the clinical trial?

National Institute of Neurological Disorders and Stroke (NINDS)Lead Sponsor
1,250 Previous Clinical Trials
452,331 Total Patients Enrolled
1 Trials studying Cushing's Disease
22 Patients Enrolled for Cushing's Disease
Prashant Chittiboina, M.D.Principal InvestigatorNational Institute of Neurological Disorders and Stroke (NINDS)
6 Previous Clinical Trials
589 Total Patients Enrolled
1 Trials studying Cushing's Disease
22 Patients Enrolled for Cushing's Disease

Eligibility Criteria

Age Any Age · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
showed a small lesion in the left anterior lobe An MRI of the pituitary gland taken within nine months of screening showed a small lesion on the left anterior lobe.
The person is a candidate for surgery to remove a pituitary tumor that is producing too much ACTH
The patient's liver function was normal as evidenced by liver enzyme tests completed within 14 days before injection of the radiopharmaceutical
the pituitary are candidates for transsphenoidal microsurgery Patients with biochemical evidence of Cushing's disease and a negative or possible adenoma (no tumor or possible tumor around) the pituitary on a clinical MRI are candidates for transsphenoidal microsurgery.
Each potential participant must be able to provide fully informed consent before participating in a study
The disease is diagnosed clinically based on medical records.
I am enrolled in the evaluation of neurosurgical disorders class, 03-N-0164.
The ability to undergo PET-imaging without general anesthesia means that the patient does not have to be unconscious for the imaging procedure.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 23rd, 2021

Last Reviewed: November 22nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.